VHCP Management III, LLC
Follow13F filer, CIK 1738053, New York, NY
VHCP Management III, LLC reported $137,578,000 across 15 holdings for the quarter ended 2018-12-31, in a 13F-HR filed 2019-02-13. Its ten largest share positions make up 93.9% of the portfolio.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-19-001655
- Period
- 2018-12-31
- Reported value
- $138M
- Holdings
- 15
- Top 10 weight
- 93.9%
- New
- 5
- Sold out
- 3
Part of the filer group Venrock Healthcare Capital Partners III, L.P.
Nimish ShahKoh Bong Y
Stakes and trades reported after 2018-12-31
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- OKUR ONKURE THERAPEUTICS INC: 13G 2,309,559 shares, 5.7% of the class, 13G filed 2026-11-20, 0001231919-26-001621Timeline
Accepted , ingested - ENTX ENTERA BIO LTD: 13G 8,861,763 shares, 5.1% of the class, 13G filed 2026-10-30, 0001738048-26-000079Timeline
Accepted , ingested - LYCA LYCIA THERAPEUTICS INC: 13G 6,850,237 shares, 11.9% of the class, 13G filed 2026-10-30, 0001738048-26-000077Timeline
Accepted , ingested - FLSC FRAZIER LIFE SCIENCES ACQ-A: 13G 700,000 shares, 9% of the class, 13G filed 2026-10-27, 0001738048-26-000075Timeline
Accepted , ingested - XFOR X4 PHARMACEUTICALS INC: 13G/A 7,644,072 shares, 7.6% of the class, 13G/A filed 2026-11-16, 0001738048-26-000100Timeline
Accepted , ingested - VOR VOR BIOPHARMA INC: 13G/A 6,443,619 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000098Timeline
Accepted , ingested - KRRO KORRO BIO INC: 13G/A 1,474,162 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000096Timeline
Accepted , ingested - JBIO JADE BIOSCIENCES INC: 13G/A 3,858,984 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000094Timeline
Accepted , ingested - HELP HELUS PHARMA INC: 13G/A 2,688,175 shares, 3.5% of the class, 13G/A filed 2026-11-16, 0001738048-26-000092Timeline
Accepted , ingested - CBIO CRESCENT BIOPHARMA INC.: 13G/A 2,228,641 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000090Timeline
Accepted , ingested - ACHV ACHIEVE LIFE SCIENCE INC: 13G/A 5,502,064 shares, 5.2% of the class, 13G/A filed 2026-11-16, 0001738048-26-000088Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| ORCHARD THERAPEUTICS PLCnew | +1,041,515 | $16.4M |
| RA PHARMACEUTICALS INCnew | +594,713 | $10.8M |
| DBV TECHNOLOGIES S Anew | +636,800 | $4.09M |
| PTGXnew | +423,176 | $2.85M |
| YUMANITY THERAPEUTICS INCnew | +848,610 | $2.75M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| ENDOCYTE INCexited | -600,000 | -$10.7M |
| APLSexited | -50,290 | -$894K |
| CHEMOCENTRYX INCexited | -39,036 | -$493K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q4 2018
Share positions as resolved from 13F-HR 0000950123-19-001655, largest first. % of portfolio is the value over $137,578,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| KALVKALVISTA PHARMACEUTICALS INC | 1,284,931 | $25.4M | 18.45% | 0 | Timeline | ||
| BCRXBIOCRYST PHARMACEUTICALS INC | 3,061,091 | $24.7M | 17.96% | 0 | Timeline | ||
| ORCHARD THERAPEUTICS PLCORCHARD THERAPEUTICS PLC | 1,041,515 | $16.4M | 11.91% | new | |||
| TRICIDA INCTRICIDA INC | 650,585 | $15.3M | 11.15% | 0 | |||
| ObsEva SAObsEva SA | 1,159,789 | $14.7M | 10.67% | 0 | |||
| RA PHARMACEUTICALS INCRA PHARMACEUTICALS INC | 594,713 | $10.8M | 7.87% | new | |||
| KINIKSA PHARMACEUTICALS LTDKINIKSA PHARMACEUTICALS LTD | 327,777 | $9.21M | 6.69% | 0 | |||
| KADMON HOLDINGS INCKADMON HOLDINGS INC | 2,388,572 | $4.97M | 3.61% | 0 | |||
| DBV TECHNOLOGIES S ADBV TECHNOLOGIES S A | 636,800 | $4.09M | 2.97% | new | |||
| MARINUS PHARMACEUTICALS INCMARINUS PHARMACEUTICALS INC | 1,258,964 | $3.61M | 2.63% | +586,693 | |||
| PTGXPROTAGONIST THERAPEUTICS INC | 423,176 | $2.85M | 2.07% | new | Timeline | ||
| YUMANITY THERAPEUTICS INCYUMANITY THERAPEUTICS INC | 848,610 | $2.75M | 2% | new | |||
| BELLEROPHON THERAPEUTICS INCBELLEROPHON THERAPEUTICS INC | 2,274,370 | $1.82M | 1.33% | 0 | |||
| GEMPHIRE THERAPEUTICS INCGEMPHIRE THERAPEUTICS INC | 869,538 | $704K | 0.51% | 0 | |||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 66,667 | $267K | 0.19% | 0 |
Sold out in Q4 2018
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| ENDOCYTE INCENDOCYTE INC | 600,000 | $10.7M | shares |
| APLSAPELLIS PHARMACEUTICALS INC | 50,290 | $894K | shares |
| CHEMOCENTRYX INCCHEMOCENTRYX INC | 39,036 | $493K | shares |
How Q4 2018 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-19-001655 | base | 2019-02-13 | acceptance time not in the bulk data set |